Search Results - "Lowder, James N"

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study by Issa, Jean-Pierre J, Prof, Roboz, Gail, Prof, Rizzieri, David, Prof, Jabbour, Elias, MD, Stock, Wendy, Prof, O'Connell, Casey, MD, Yee, Karen, MD, Tibes, Raoul, MD, Griffiths, Elizabeth A, MD, Walsh, Katherine, MD, Daver, Naval, MD, Chung, Woonbok, PhD, Naim, Sue, BS, Taverna, Pietro, PhD, Oganesian, Aram, PhD, Hao, Yong, MD, Lowder, James N, MD, Azab, Mohammad, MD, Kantarjian, Hagop, Prof

“…Summary Background Hypomethylating agents are used to treat cancers driven by aberrant DNA methylation, but their short half-life might limit their activity,…”
Get full text

Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy by Fazio, Carolina, Covre, Alessia, Cutaia, Ornella, Lofiego, Maria Fortunata, Tunici, Patrizia, Chiarucci, Carla, Cannito, Sara, Giacobini, Gianluca, Lowder, James N, Ferraldeschi, Roberta, Taverna, Pietro, Di Giacomo, Anna Maria, Coral, Sandra, Maio, Michele

“…DNA hypomethylating agents (DHAs) play a well-acknowledged role in potentiating the immunogenicity and the immune recognition of neoplastic cells. This…”
Get full text

SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial by Crabb, Simon, Danson, Sarah J, Catto, James W F, McDowell, Cathy, Lowder, James N, Caddy, Joshua, Dunkley, Denise, Rajaram, Jessica, Ellis, Deborah, Hill, Stephanie, Hathorn, David, Whitehead, Amy, Kalevras, Mihalis, Huddart, Robert, Griffiths, Gareth

“…Urothelial bladder cancer (UBC) accounts for 10,000 new diagnoses and 5000 deaths annually in the UK (Cancer Research UK,…”
Get full text

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia by Roboz, Gail J., Kantarjian, Hagop M., Yee, Karen W. L., Kropf, Patricia L., O'Connell, Casey L., Griffiths, Elizabeth A., Stock, Wendy, Daver, Naval G., Jabbour, Elias, Ritchie, Ellen K., Walsh, Katherine J., Rizzieri, David, Lunin, Scott D., Curio, Tania, Chung, Woonbok, Hao, Yong, Lowder, James N., Azab, Mohammad, Issa, Jean‐Pierre J.

“…BACKGROUND Outcomes for patients with relapsed or refractory acute myeloid leukemia (AML) are poor. Guadecitabine, a next‐generation hypomethylating agent,…”
Get full text

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma by Alva, Ajjai, Daniels, Gregory A., Wong, Michael K. K., Kaufman, Howard L., Morse, Michael A., McDermott, David F., Clark, Joseph I., Agarwala, Sanjiv S., Miletello, Gerald, Logan, Theodore F., Hauke, Ralph J., Curti, Brendan, Kirkwood, John M., Gonzalez, Rene, Amin, Asim, Fishman, Mayer, Agarwal, Neeraj, Lowder, James N., Hua, Hong, Aung, Sandra, Dutcher, Janice P.

“…High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an…”
Get full text

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014 by Dutcher, Janice P, Schwartzentruber, Douglas J, Kaufman, Howard L, Agarwala, Sanjiv S, Tarhini, Ahmad A, Lowder, James N, Atkins, Michael B

“…Interleukin-2 (IL-2) was historically one of the few treatments for adults with stage IV solid tumors that could produce complete responses (CRs) that were…”
Get full text

Abstract 2325: Immune checkpoint(s) expression in AML patients enrolled in a phase 1-2 study with guadecitabine by Fazio, Carolina, Covre, Alessia, Lofiego, Maria, Taverna, Pietro, Azab, Mohammad, Lowder, James N., Coral, Sandra, Maio, Michele

“…Abstract Immune checkpoint(s) blockade is becoming the therapeutic mainstay in melanoma and lung cancer. Based on these important clinical achievements,…”
Get full text

Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis by Sandborn, William J, Colombel, Jean Frederic, Frankel, Matthew, Hommes, Daan, Lowder, James N, Mayer, Lloyd, Plevy, Scott, Stokkers, Pieter, Travis, Simon, Van Assche, Gert, Baumgart, Daniel C, Targan, Stephan R

“…Pilot studies with visilizumab, a humanised monoclonal antibody to CD3, suggest efficacy for corticosteroid-refractory ulcerative colitis (UC). A…”
Get more information

Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy? by Lowder, James N, Taverna, Pietro, Issa, Jean-Pierre J

“…Longer exposure would logically affect more cells and enhance efficacy. [...]the clinical activity of these agents is highly dose- and schedule-sensitive (5)…”
Get full text

Prospective randomized open‐label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid‐refractory ulcerative colitis by Baumgart, Daniel C., Targan, Stephan R., Dignass, Axel U., Mayer, Lloyd, Assche, Gert van, Hommes, Daan W., Hanauer, Stephen B., Mahadevan, Uma, Reinisch, Walter, Plevy, Scott E., Salzberg, Bruce A., Buchman, Alan L., Mechkov, Grigor M., Krastev, Zahariy A., Lowder, James N., Frankel, Matthew B., Sandborn, William J.

“…Background: Visilizumab is a humanized IgG2 monoclonal anti‐CD3 antibody. We evaluated its safety and dose response in severe intravenous steroid‐refractory…”
Get full text

Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies by Xu, Cong, Goggin, Timothy K., Su, Xiang‐Yao, Taverna, Pietro, Oganesian, Aram, Lowder, James N., Azab, Mohammad, Kantarjian, Hagop

“…Guadecitabine (SGI‐110) is a novel next‐generation hypomethylating agent (HMA) administered as s.c. injection with extended decitabine exposure…”
Get full text

Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease by Baumgart, Daniel C, Lowder, James N, Targan, Stephan R, Sandborn, William J, Frankel, Matthew B

“…Monoclonal antibodies to CD3 and CD4 T-cell receptors are evolving for Crohn's disease (CD) and ulcerative colitis. Their administration is often associated…”
Get full text

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2) by Kaufman, Howard L, Wong, Michael K, Daniels, Gregory A, McDermott, David F, Aung, Sandra, Lowder, James N, Morse, Michael A

“…Registries evaluating un-randomized patients have provided valuable information with respect to a therapy's utility, treatment practices, and evolution over…”
Get full text

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes by Wong, Michael K, Kaufman, Howard L, Daniels, Gregory A, McDermott, David F, Aung, Sandra, Lowder, James N, Morse, Michael A

“…Cancer registries have proven valuable with respect to validating therapeutic safety and drug efficacy, uncovering real-world implementation practices, and…”
Get full text

Abstract CT059: Epigenetic tumor remodelling to improve the efficacy of immune checkpoint blockade: the NIBIT-M4 clinical trial by Giacomo, Anna M. Di, Covre, Alessia, Finotello, Francesca, Rieder, Dietmar, Sigalotti, Luca, Fazio, Carolina, Cutaia, Ornella, Bock, Christoph, Petitprez, Florent, Lacroix, Laetitia, Lowder, James N., Fridman, Wolf H., Sautès-Fridman, Catherine, Trajanoski, Zlatko, Maio, Michele

“…Abstract Introduction: The anti-CTLA-4 monoclonal antibody (mAb) ipilimumab (Ipi) has firstly shown the therapeutic potential of targeting immune checkpoints…”
Get full text

Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study by Di Giacomo, Anna Maria, Covre, Alessia, Finotello, Francesca, Rieder, Dietmar, Sigalotti, Luca, Giannarelli, Diana, Petitprez, Florent, Lacroix, Laetitia, Cutaia, Ornella, Fazio, Carolina, Coral, Sandra, Anichini, Andrea, Bock, Christoph, Lowder, James N., Azab, Mohammad, Fridman, Wolf-Herman, Sautes-Fridman, Catherine, Trajanoski, Zlatko, Maio, Michele

“…Abstract only 2549 Background: DNA hypomethylating agents show broad immuno-modulatory activity in neoplastic cells, and may improve the effectiveness of…”
Get full text

A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 study by Di Giacomo, Anna Maria, Covre, Alessia, Taverna, Pietro, Coral, Sandra, Amato, Giovanni, Keer, Harold N., Lowder, James N., Giannarelli, Diana, Azab, Mohammad, Maio, Michele

“…Abstract only…”
Get full text

Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study by Garcia-Manero, Guillermo, Odenike, Olatoyosi, Amrein, Philip C., Steensma, David P., DeZern, Amy E., Michaelis, Laura C., Faderl, Stefan, Kantarjian, Hagop M., Lowder, James N., Taverna, Pietro, Oganesian, Aram, Zhang, Xiaoping, Azab, Mohammad, Savona, Michael R.

“…▪ Introduction: Patients with International Prognostic Scoring System (IPSS) intermediate 1 and 2 (Int) and high risk (HR) MDS benefit from therapy with…”
Get full text

A Phase 2 Dose-Confirmation Study of Oral ASTX727, a Combination of Oral Decitabine with a Cytidine Deaminase Inhibitor (CDAi) Cedazuridine (E7727), in Subjects with Myelodysplastic Syndromes (MDS) by Garcia-Manero, Guillermo, Griffiths, Elizabeth A., Roboz, Gail J., Busque, Lambert, Wells, Richard A., Odenike, Olatoyosi, Steensma, David P., Yee, Karen W.L., Faderl, Stefan, Amrein, Philip C., Michaelis, Laura C., Kantarjian, Hagop M., Oganesian, Aram, Lowder, James N., Azab, Mohammad, Savona, Michael R.

“…Aims: A combination of oral decitabine (DAC), a drug normally parenterally administered, with an oral cytidine deaminase inhibitor (CDAi), enhances its…”
Get full text

Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry by Daniels, Gregory A., Morse, Michael, Wong, Michael K.K., Kaufman, Howard, McDermott, David F., Aung, Sandra, Lowder, James N.

“…Abstract only…”
Get full text